Hemostemix Inc. HEM.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · hemostemix.com
Hemostemix Inc. is a clinical-stage biotechnology company headquartered in Calgary, Canada, that develops blood-derived stem cell therapies. Its lead product, ACP-01, is in Phase II clinical trials for vascular diseases including peripheral arterial disease, angina pectoris, chronic limb threatening ischemia, and heart failure. The company also develops NCP-01, a preclinical product targeting neuropathic pain and motor function recovery.
Key ratios
ReturnOnAssets TTM -3.69
ReturnOnAssets 2025 -3.58
ReturnOnAssets 2024 -1.89
ReturnOnAssets 2023 -3.74
Recent news
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
2026-07-30 · Newsfile
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell's Excellent Results
2026-07-28 · Newsfile
Hemostemix Grants Stock Options
2026-07-22 · Newsfile
Hemostemix Closes $360,000 First Tranche of Private Placement
2026-06-26 · BioSpace
Hemostemix' $1,000,000 Private Placement and Update
2026-06-18 · BioSpace
Hemostemix Receives FDA Support for Its Basket Protocol Approach
2026-01-16 · Newsfile Corp